E
E. Felip
Researcher at University of Texas Health Science Center at San Antonio
Publications - 94
Citations - 1120
E. Felip is an academic researcher from University of Texas Health Science Center at San Antonio. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 9, co-authored 36 publications receiving 610 citations.
Papers
More filters
Journal ArticleDOI
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paul K. Paik,E. Felip,Remi Veillon,Hiroshi Sakai,Alexis B. Cortot,Marina Chiara Garassino,J. Mazieres,Santiago Viteri,Hélène Senellart,Jan van Meerbeeck,Jo Raskin,Niels Reinmuth,Pierfranco Conte,Dariusz M. Kowalski,Byoung Chul Cho,Jyoti D. Patel,Leora Horn,Frank Griesinger,Ji Youn Han,Young Chul Kim,Gee Chen Chang,Chen Liang Tsai,James Chih-Hsin Yang,Yuh Min Chen,Egbert F. Smit,Anthonie J. van der Wekken,Terufumi Kato,Dilafruz Juraeva,Christopher Stroh,Rolf Bruns,J. Straub,Andreas Johne,Jürgen Scheele,J. Heymach,Xiuning Le +34 more
TL;DR: Among patients with advanced NSCLC with a confirmed MET exon 14 skipping mutation, the use of tepotinib was associated with a partial response in approximately half the patients, and adverse events led to permanent discontinuation of tEPotinib in 11% of the patients.
Journal ArticleDOI
Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.
Rosa Rosell,Radj Gervais,A. Vergnenegre,B. Massuti,E. Felip,Felipe Cardenal,R. Garcia Gomez,Cinta Pallares,J. M. Sanchez,R. Porta,M. Cobo,M. Di Seri,P. Garrido Lopez,A. Insa,F. De Marinis,Romain Corre,M. Carreras,Enric Carcereny,M. Taron,Luis Paz-Ares +19 more
TL;DR: The EURTAC study met its primary endpoint at the interim analysis, and erlotinib as first-line treatment for advanced NSCLC p with EGFR mutations improves PFS, with acceptable toxicity, compared to platinum-based chemotherapy.
Journal ArticleDOI
NSCLC, metastaticCheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC
Mark A. Socinski,Benjamin C. Creelan,Leora Horn,Martin Reck,Luis Paz-Ares,Martin Steins,E. Felip,M. van den Heuvel,Tudor-Eliade Ciuleanu,Firas Benyamine Badin,Neal Ready,Thijo J N Hiltermann,Suresh G. Nair Md,Rosalyn A. Juergens,Solange Peters,Elisa Minenza,William J. Geese,Prabhu Bhagavatheeswaran,Allen C. Chen,David P. Carbone +19 more
Journal ArticleDOI
PHASE II ACTIVITY OF THE HSP90 INHIBITOR AUY922 IN PATIENTS WITH ALK-REARRANGED (ALK plus ) OR EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
E. Felip,Enric Carcereny,Fabrice Barlesi,L. Gandhi,Lecia V. Sequist,S-W. Kim,Hendricus Groen,Benjamin Besse,D-W. Kim,Egbert F. Smit,Mikhail Akimov,Emin Avsar,Stuart Bailey,W. Ofosu-Appiah,Edward B. Garon +14 more
TL;DR: AUY922 had an acceptable safety profile and clinical activity was seen in pts with ALK+ and EGFR-mut NSCLC, with partial responses in 6/21 (29%) pts and 7/35 (20%) pts, respectively, and response and PFS rates suggest further studies are warranted in these patient populations, particularly in EGfr-mut pts who progressed following treatment with TKIs.
Journal ArticleDOI
ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer.
Antonio Passaro,NB Leighl,Fiona H Blackhall,Sanjay Popat,Kelsey Kerr,M. Ahn,Maria E. Arcila,Oscar Arrieta,David Planchard,Filippo de Marinis,A.-M. C. Dingemans,Rafal Dziadziuszko,Corinne Faivre-Finn,Jill Elizabeth Feldman,E. Felip,Giuseppe Curigliano,Roy S. Herbst,Pasi A. Jänne,Thomas John,Tetsuya Mitsudomi,Tony Mok,Nicola Normanno,Luiz Paz-Ares,S.S. Ramalingam,Lecia V. Sequist,Johan Vansteenkiste,Ignacio I. Wistuba,Jonathan Wolf,Y. Wu,S. Yang,J.C-H. Yang,Y. Yatabe,George Pentheroudakis,S. Peters +33 more
TL;DR: The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer in 2021 as discussed by the authors .